Latent Mycobacterium tuberculosis infection

New England Journal of Medicine

Volumn 372, Issue 22, 2015, Pages 2127-2135

  Getahun, Haileyesus ^a   Matteelli, Alberto ^a   Chaisson, Richard E ^b   Raviglione, Mario ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATOVAQUONE; CARBAMAZEPINE; CHLORAMPHENICOL; CLARITHROMYCIN; CYCLOSPORIN; DISULFIRAM; DOLUTEGRAVIR; DOXYCYCLINE; EFAVIRENZ; ELVITEGRAVIR; ERYTHROMYCIN; GLUCOCORTICOID; ISONIAZID; MARAVIROC; MEFLOQUINE; METHADONE; PARACETAMOL; PLACEBO; PYRAZINAMIDE; PYRROLE; RIFAMPICIN; RIFAPENTINE; RILPIVIRINE; THEOPHYLLINE; TRIAZOLAM; UNINDEXED DRUG; VALPROIC ACID; WARFARIN; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ACUTE KIDNEY TUBULE NECROSIS; ALLERGIC REACTION; ANOREXIA; DISEASE COURSE; DISEASE TRANSMISSION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HUMAN; HYPOTENSION; INTERFERON GAMMA RELEASE ASSAY; INTERSTITIAL NEPHRITIS; LATENT TUBERCULOSIS; LIVER TOXICITY; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); MONOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEIZURE; THROMBOCYTOPENIA; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT WITHDRAWAL; TUBERCULIN TEST; VOMITING; ANALOGS AND DERIVATIVES; DRUG ADMINISTRATION; DRUG COMBINATION; PRACTICE GUIDELINE; RISK FACTOR;

ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINES AS TOPIC; RIFAMPIN; RISK FACTORS;

EID: 84929846820     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1405427     Document Type: Review

References (58)

1. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009;33:956-73.
2. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974;99:131-8.
3. Parfitt CD. Osler's influence in the war against tuberculosis (The Fifth Osler Oration). Can Med Assoc J 1942;47:293-304.
4. Modlin RL, Bloom BR. TB or not TB: that is no longer the question. Sci Transl Med 2013;5:213sr6.
5. Achkar JM, Jenny-Avital ER. Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response. J Infect Dis 2011;204:Suppl 4:S1179-S1186.
6. Zhang G, Zhou B, Li S, et al. Allelespecific induction of IL-1β expression by C/EBPβ and PU.1 contributes to increased tuberculosis susceptibility. PLoS Pathog 2014;10(10):e1004426.
7. Orme IM. A new unifying theory of the pathogenesis of tuberculosis. Tuberculosis (Edinb) 2014;94:8-14.
8. O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annu Rev Immunol 2013;31:475-527.
9. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-21.
10. Shanaube K, Sismanidis C, Ayles H, et al. Annual risk of tuberculous infection using different methods in communities with a high prevalence of TB and HIV in Zambia and South Africa. PLoS One 2009;4(11):e7749.
11. Hoa NB, Cobelens FG, Sy DN, Nhung NV, Borgdorff MW, Tiemersma EW. First national tuberculin survey in Viet Nam: characteristics and association with tuberculosis prevalence. Int J Tuberc Lung Dis 2013;17:738-44.
12. Daniel TM, Debanne SM. Estimation of the annual risk of tuberculosis infection for white men in the United States. J Infect Dis 1997;175:1535-7.
13. Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR Jr. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol 2014;179:216-25.
14. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-50.
15. Keane J, Bresnihan B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr Opin Rheumatol 2008;20:443-9.
16. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006;55:19-26.
17. Sidhu A, Verma G, Humar A, Kumar D. Outcome of latent tuberculosis infection in solid organ transplant recipients over a 10-year period. Transplantation 2014;98:671-5.
18. Al-Anazi KA, Al-Jasser AM, Alsaleh K. Infections caused by Mycobacterium tuberculosis in recipients of hematopoietic stem cell transplantation. Front Oncol 2014;4:231.
19. Christopoulos AI, Diamantopoulos AA, Dimopoulos PA, Goumenos DS, Barbalias GA. Risk factors for tuberculosis in dialysis patients: a prospective multi-center clinical trial. BMC Nephrol 2009;10:36.
20. Corbett EL, Churchyard GJ, Clayton TC, et al. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS 2000;14:2759-68.
21. Baussano I, Williams BG, Nunn P, Beggiato M, Fedeli U, Scano F. Tuberculosis incidence in prisons: a systematic review. PLoS Med 2010;7(12):e1000381.
22. Selwyn PA, Schoenbaum EE, Davenny K, et al. Prospective study of human immunodeficiency virus infection and pregnancy outcomes in intravenous drug users. JAMA 1989;261:1289-94.
23. Moss AR, Hahn JA, Tulsky JP, Daley CL, Small PM, Hopewell PC. Tuberculosis in the homeless: a prospective study. Am J Respir Crit Care Med 2000;162:460-4.
24. Banfield S, Pascoe E, Thambiran A, Siafarikas A, Burgner D. Factors associated with the performance of a bloodbased interferon-γ release assay in diagnosing tuberculosis. PLoS One 2012;7(6):e38556.
25. Katsenos S, Nikolopoulou M, Gartzonika C, et al. Use of interferon-gamma release assay for latent tuberculosis infection screening in older adults exposed to tuberculosis in a nursing home. J Am Geriatr Soc 2011;59:858-62.
26. Dorman SE, Belknap R, Graviss EA, et al. Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med 2014;189:77-87.
27. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008;5(7):e152.
28. Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 2014;27:3-20.
29. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012;142:63-75.
30. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:45-55.
31. Haldar P, Thuraisingam H, Patel H, et al. Single-step QuantiFERON screening of adult contacts: a prospective cohort study of tuberculosis risk. Thorax 2013;68:240-6.
32. Piccazzo R, Paparo F, Garlaschi G. Diagnostic accuracy of chest radiography for the diagnosis of tuberculosis (TB) and its role in the detection of latent TB infection: a systematic review. J Rheumatol Suppl 2014;91:32-40.
33. Chegou NN, Heyckendorf J, Walzl G, Lange C, Ruhwald M. Beyond the IFN-γ horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis. Eur Respir J 2014;43:1472-86.
34. Horsburgh CR Jr, Rubin EJ. Latent tuberculosis infection in the United States. N Engl J Med 2011;364:1441-8.
35. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010;1:CD000171.
36. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847-50.
37. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000;2:CD001363.
38. Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet 2014;384:682-90.
39. Kirenga BJ, Worodria W, Massinga-Loembe M, et al. Tuberculin skin test conversion among HIV patients on antiretroviral therapy in Uganda. Int J Tuberc Lung Dis 2013;17:336-41.
40. Churchyard GJ, Fielding KL, Grant AD. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med 2014;370:1662-3.
41. Golub JE, Cohn S, Saraceni V, et al. Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis 2015;60:639-45.
42. Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med 2014;161:419-28.
43. McElroy PD, Ijaz K, Lambert LA, et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2005;41:1125-33.
44. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008;149:689-97.
45. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155-66.
46. Villarino ME, Scott NA, Weis SE, et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr 2015;169:247-55.
47. st Conference on Retroviruses and Opportunistic Infections (CROI 2014), Boston, March 3-6, 2014 (poster).
48. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011;365:11-20.
49. st Conference on Retroviruses and Opportunistic Infections (CROI 2014), Boston, March 3-6, 2014 (poster).
50. Shepardson D, Marks SM, Chesson H, et al. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis 2013;17:1531-7.
51. Seddon JA, Hesseling AC, Finlayson H, et al. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis 2013;57:1676-84.
52. Bamrah S, Brostrom R, Dorina F, et al. Treatment for LTBI in contacts of MDR-TB patients, federated states of Micronesia, 2009-2012. Int J Tuberc Lung Dis 2014;18:912-8.
53. Horsburgh CR Jr, Goldberg S, Bethel J, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010;137:401-9.
54. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 2008;12:1235-54.
55. Hirsch-Moverman Y, Shrestha-Kuwahara R, Bethel J, et al. Latent tuberculous infection in the United States and Canada: who completes treatment and why? Int J Tuberc Lung Dis 2015;19:31-8.
56. Guidelines on the Management of Latent Tuberculosis Infection. Geneva: World Health Organization, 2015 (http://apps.who.int/medicinedocs/documents/s21682en/s21682en.pdf).
57. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011;8(1):e1000391.
58. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. Annu Rev Public Health 2013;34:271-86.